Branched chain amino acids and major depressive disorder in a sample of healthy, non-obese people.

Background : Major depressive disorder (MDD) is the most prevalent neurological condition and a significant global public health challenge. Existing pharmacological treatments often have limited efficacy and are associated with substantial side effects. Branched-chain amino acids (BCAAs) have emerged as a potential novel intervention for MDD. However, there is limited research on the relationship between plasma BCAA concentrations and MDD in population-based studies, and the sample sizes of these studies are typically small. Method : This cross-sectional study utilized data from the CoLaus|PsyCoLaus cohort (Lausanne, Switzerland). BCAA concentrations were measured using stable isotope dilution liquid chromatography–mass spectrometry. MDD status was assessed via questionnaire and categorized as “Current” “Remitted “and “No”. Result : Data from 2,182 participants (mean age 53.25 ± 8.5 years, 58.07% women) were analyzed. Bivariate analysis revealed a significant difference in BCAA levels between the "Remitted" and "No" MDD groups. However, after multivariable analysis with adjustment for gender, all associations disappeared. Conclusion : There is no significant association between BCAA levels and MDD in healthy, non-obese and old people.